Logo

Amgen Reports Results of ABP 654 (biosimilar, ustekinumab) in P-III Study for the Treatment of Plaque Psoriasis

Share this
Amgen Reports Results of ABP 654 (biosimilar, ustekinumab) in P-III Study for the Treatment of Plaque Psoriasis

Amgen Reports Results of ABP 654 (biosimilar, ustekinumab) in P-III Study for the Treatment of Plaque Psoriasis

Shots:

  • The company reported the preliminary results from a P-III study to evaluate the safety and efficacy of ABP 654 vs Stelara (ustekinumab) in 563 adult patients with mod. to sev. PsO
  • The study met the primary efficacy EPs i.e., the therapy showed no clinical differences b/w ABP 654 and Stelara & also evaluated an improvement from baseline to 12wk. of PASI which showed a mean difference of percentage improvement b/w ABP 654 and Stelara. The safety profile of ABP 654 was comparable to Stelara
  • Stelara (ustekinumab) is a human interleukin-12 & 23 antagonists indicated for the treatment of moderate to severe PsO in adults and pediatric patients aged ≥6yrs.

Ref: PR Newswire | Image: Adweek

Click here to­ read the full press release 

Neha

Neha Madan is a content writer at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions